Janney Montgomery Scott LLC reduced its stake in DaVita Inc. (NYSE:DVA – Get Rating) by 7.2% during the third quarter, HoldingsChannel reports. The firm owned 7,163 shares of the company’s stock after selling 553 shares during the period. Janney Montgomery Scott LLC’s holdings in DaVita were worth $593,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Raymond James & Associates raised its position in DaVita by 4.0% during the first quarter. Raymond James & Associates now owns 22,651 shares of the company’s stock valued at $2,562,000 after purchasing an additional 865 shares in the last quarter. American Century Companies Inc. lifted its position in DaVita by 37.4% in the 1st quarter. American Century Companies Inc. now owns 6,555 shares of the company’s stock worth $741,000 after buying an additional 1,785 shares during the last quarter. US Bancorp DE boosted its stake in DaVita by 63.6% in the first quarter. US Bancorp DE now owns 2,998 shares of the company’s stock worth $338,000 after buying an additional 1,166 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in DaVita by 7.3% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,551 shares of the company’s stock valued at $402,000 after acquiring an additional 242 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of DaVita by 847.8% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,090 shares of the company’s stock worth $123,000 after acquiring an additional 975 shares in the last quarter. Hedge funds and other institutional investors own 86.52% of the company’s stock.
DaVita Stock Up 1.0 %
Shares of DaVita stock opened at $80.32 on Friday. The company’s fifty day simple moving average is $74.65 and its two-hundred day simple moving average is $82.19. DaVita Inc. has a 12-month low of $65.28 and a 12-month high of $124.81. The company has a current ratio of 1.26, a quick ratio of 1.22 and a debt-to-equity ratio of 12.63. The company has a market cap of $7.24 billion, a P/E ratio of 11.76, a PEG ratio of 1.45 and a beta of 0.96.
Insider Activity at DaVita
In other news, Director John M. Nehra acquired 5,000 shares of DaVita stock in a transaction on Tuesday, November 1st. The stock was acquired at an average cost of $71.14 per share, for a total transaction of $355,700.00. Following the purchase, the director now owns 15,000 shares in the company, valued at $1,067,100. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several equities analysts recently commented on DVA shares. Truist Financial reduced their target price on shares of DaVita from $90.00 to $75.00 and set a “hold” rating on the stock in a report on Monday, October 31st. TheStreet lowered DaVita from a “b-” rating to a “c+” rating in a research note on Tuesday, November 1st. UBS Group lowered DaVita from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $117.00 to $74.00 in a research report on Monday, October 31st. Deutsche Bank Aktiengesellschaft lowered DaVita from a “buy” rating to a “hold” rating and dropped their price objective for the company from $97.00 to $72.00 in a research note on Tuesday, November 1st. Finally, Barclays dropped their price target on shares of DaVita from $103.00 to $81.00 and set an “equal weight” rating for the company in a research report on Monday, October 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $81.17.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.